Oct 29, 2018 8:00am EDT Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE™ (fostamatinib disodium hexahydrate) in Japan and other Asian Countries
Oct 11, 2018 7:30am EDT Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
Aug 29, 2018 7:30am EDT Rigel to Present at the 20th Annual Global Investment Conference in New York City
Aug 08, 2018 4:07pm EDT Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update
Aug 01, 2018 7:30am EDT Rigel Announces Conference Call and Webcast to Report Second Quarter 2018 Financial Results
Jun 26, 2018 7:30am EDT Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases
Jun 12, 2018 7:30am EDT Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA
